A Multicenter, Single-Arm, Open-Label Study of the Efficacy and Safety of CC-5013 Monotherapy in Red Blood Cell Transfusion-Dependent Subjects With Myelodysplastic Syndromes Associated With a Del (5q) Cytogenetic Abnormality

Trial Profile

A Multicenter, Single-Arm, Open-Label Study of the Efficacy and Safety of CC-5013 Monotherapy in Red Blood Cell Transfusion-Dependent Subjects With Myelodysplastic Syndromes Associated With a Del (5q) Cytogenetic Abnormality

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 Dec 2015 Pooled analysis of 2 trials (n=286) including this study and another study [see CTP 700006777] were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2015 Results of pooled analysis on conditional survival analysis (n=286), presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 09 Dec 2013 Association between cytogenetic response and RBC-TI and AML-free survival in MDS003 and MDS004 study patients reported at 55th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top